Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals
Top Cited Papers
- 16 April 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Applied Microbiology and Biotechnology
- Vol. 68 (3), 283-291
- https://doi.org/10.1007/s00253-005-1980-8
Abstract
There has been a rapid increase in the number and demand for approved biopharmaceuticals produced from animal cell culture processes over the last few years. In part, this has been due to the efficacy of several humanized monoclonal antibodies that are required at large doses for therapeutic use. There have also been several identifiable advances in animal cell technology that has enabled efficient biomanufacture of these products. Gene vector systems allow high specific protein expression and some minimize the undesirable process of gene silencing that may occur in prolonged culture. Characterization of cellular metabolism and physiology has enabled the design of fed-batch and perfusion bioreactor processes that has allowed a significant improvement in product yield, some of which are now approaching 5 g/L. Many of these processes are now being designed in serum-free and animal-component-free media to ensure that products are not contaminated with the adventitious agents found in bovine serum. There are several areas that can be identified that could lead to further improvement in cell culture systems. This includes the down-regulation of apoptosis to enable prolonged cell survival under potentially adverse conditions. The characterization of the critical parameters of glycosylation should enable process control to reduce the heterogeneity of glycoforms so that production processes are consistent. Further improvement may also be made by the identification of glycoforms with enhanced biological activity to enhance clinical efficacy. The ability to produce the ever-increasing number of biopharmaceuticals by animal cell culture is dependent on sufficient bioreactor capacity in the industry. A recent shortfall in available worldwide culture capacity has encouraged commercial activity in contract manufacturing operations. However, some analysts indicate that this still may not be enough and that future manufacturing demand may exceed production capacity as the number of approved biotherapeutics increases.Keywords
This publication has 67 references indexed in Scilit:
- Life and death in mammalian cell culture: strategies for apoptosis inhibitionTrends in Biotechnology, 2004
- Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cellsBiotechnology & Bioengineering, 2003
- Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencingGenomics, 2003
- Therapeutic antibodies for human diseases at the dawn of the twenty-first centuryNature Reviews Drug Discovery, 2003
- Recombinant protein expression for therapeutic applicationsCurrent Opinion in Biotechnology, 2002
- Metabolic control of recombinant proteinN-glycan processing in NS0 and CHO cellsBiotechnology & Bioengineering, 2001
- Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activatorBiotechnology & Bioengineering, 2000
- Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sortingBiotechnology & Bioengineering, 2000
- In Pursuit of the Optimal Fed‐Batch Process for Monoclonal Antibody ProductionBiotechnology Progress, 1995
- The effect of cell-culture conditions on the oligosaccharide structures of secreted glycoproteinsCurrent Opinion in Biotechnology, 1994